J. M. Sanchez

667 total citations
15 papers, 499 citations indexed

About

J. M. Sanchez is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, J. M. Sanchez has authored 15 papers receiving a total of 499 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in J. M. Sanchez's work include Lung Cancer Treatments and Mutations (6 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Lung Cancer Research Studies (3 papers). J. M. Sanchez is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer, Hypoxia, and Metabolism (3 papers) and Lung Cancer Research Studies (3 papers). J. M. Sanchez collaborates with scholars based in Spain, United States and Italy. J. M. Sanchez's co-authors include Bartomeu Massutí, Luis Paz‐Ares, A. García, Guillermo López-Vivanco, Mariano Provencio, María L. Amador, Rafael Rosell, Ana Fernández Montés, Miguel Quintela-Fandiño and Silvana Mourón and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cell Reports.

In The Last Decade

J. M. Sanchez

15 papers receiving 483 citations

Peers

J. M. Sanchez
Kevin Jao Canada
Jean‐Charles Soria France
Chee-Seng Tan Singapore
Eric D. Mininberg United States
Giuseppe Colantuoni Italy
J. Zugazagoitia Spain
M.R. García Campelo Spain
N. Iannino Canada
Feiyu Niu China
Annamaria Siggillino Italy
Kevin Jao Canada
J. M. Sanchez
Citations per year, relative to J. M. Sanchez J. M. Sanchez (= 1×) peers Kevin Jao

Countries citing papers authored by J. M. Sanchez

Since Specialization
Citations

This map shows the geographic impact of J. M. Sanchez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. M. Sanchez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. M. Sanchez more than expected).

Fields of papers citing papers by J. M. Sanchez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. M. Sanchez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. M. Sanchez. The network helps show where J. M. Sanchez may publish in the future.

Co-authorship network of co-authors of J. M. Sanchez

This figure shows the co-authorship network connecting the top 25 collaborators of J. M. Sanchez. A scholar is included among the top collaborators of J. M. Sanchez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. M. Sanchez. J. M. Sanchez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Hütter, Stephan, Carmelo Gurnari, J. M. Sanchez, et al.. (2022). Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes. Nature Communications. 13(1). 1038–1038. 28 indexed citations
2.
Massutí, Bartomeu, Manuel Cobo, Iván Ballesteros, et al.. (2017). PL 02.04 SCAT Ph III Trial: Adjuvant CT Based on BRCA1 Levels in NSCLC N+ Resected Patients. Final Survival Results a Spanish Lung Cancer Group Trial. Journal of Thoracic Oncology. 12(11). S1605–S1605. 5 indexed citations
3.
Bueno, María J., J. M. Sanchez, Rámón Colomer, & Miguel Quintela-Fandiño. (2016). Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors. Current Drug Targets. 17(15). 1735–1746. 4 indexed citations
4.
Navarro, Paloma, María J. Bueno, J. M. Sanchez, et al.. (2016). Targeting Tumor Mitochondrial Metabolism Overcomes Resistance to Antiangiogenics. Cell Reports. 15(12). 2705–2718. 78 indexed citations
5.
Soto‐Montenegro, María Luisa, Diego Megı́as, Silvana Mourón, et al.. (2015). Monitoring vascular normalization induced by antiangiogenic treatment with 18F‐fluoromisonidazole‐PET. Molecular Oncology. 10(5). 704–718. 34 indexed citations
6.
González‐Cao, María, Jordi Rodón, Niki Karachaliou, et al.. (2015). Other targeted drugs in melanoma.. PubMed. 3(18). 266–266. 12 indexed citations
7.
Merlos, Pilar, Eva Rúmiz, Ricardo Ruiz‐Granell, et al.. (2012). Outcome of patients with syncope beyond the implantable loop recorder. EP Europace. 15(1). 122–126. 8 indexed citations
8.
Massutí, Bartomeu, Ulpiano Jiménez, J.M. Rodríguez Paniagua, et al.. (2011). SCAT trial: Phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer.. Journal of Clinical Oncology. 29(15_suppl). TPS208–TPS208. 1 indexed citations
9.
Carcereny, Enric, Matias Molina, José Javier Sánchez, et al.. (2011). Mutations of the catalytic subunit a of PI3K (PIK3CA) in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations.. Journal of Clinical Oncology. 29(15_suppl). 7588–7588. 8 indexed citations
10.
11.
12.
Paz‐Ares, Luis, J. M. Sanchez, A. García, et al.. (2006). A prospective phase II trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). Journal of Clinical Oncology. 24(18_suppl). 7020–7020. 125 indexed citations
13.
Socinski, Mark A., Silvia Novello, J. M. Sanchez, et al.. (2006). Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. Journal of Clinical Oncology. 24(18_suppl). 7001–7001. 79 indexed citations
14.
Sanchez, J. M., Petr Zatloukal, Michael C. Perry, et al.. (2004). A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7248–7248. 2 indexed citations
15.
Carles, Joan, Mariano Monzó, Rosa Artells, et al.. (2004). XPC, XPD/ERCC2, UMPS, CYP1b1 and XRCC5, single nucleotide polymorphisms (SNPs) in head and neck cancer. Journal of Clinical Oncology. 22(14_suppl). 5588–5588. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kevin Jao Breakdown of academic impact, for papers by Jean‐Charles Soria Breakdown of academic impact, for papers by Chee-Seng Tan Breakdown of academic impact, for papers by Eric D. Mininberg Breakdown of academic impact, for papers by Giuseppe Colantuoni Breakdown of academic impact, for papers by J. Zugazagoitia Breakdown of academic impact, for papers by M.R. García Campelo Breakdown of academic impact, for papers by N. Iannino Breakdown of academic impact, for papers by Feiyu Niu Breakdown of academic impact, for papers by Annamaria Siggillino
Rankless by CCL
2026